학술논문
Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.
Document Type
Article
Author
Montejo, Ángel L.; Arango, Celso; Bernardo, Miquel; Carrasco, José L.; Crespo-Facorro, Benidicto; Cruz, Juan J.; Del Pino-Montes, Javier; García-Escudero, Miguel A.; García-Rizo, Clemente; González-Pinto, Ana; Hernández, Ana I.; Martín-Carrasco, Manuel; Mayoral-Cleries, Fermín; Mayoral-van Son, Jaqueline; Mories, M. Teresa; Pachiarotti, Isabella; Pérez, Jesús; Ros, Salvador; Vieta, Eduard
Source
Subject
*HYPERPROLACTINEMIA
*ANTIPSYCHOTIC agents
*IATROGENIC diseases
*PERSONALITY disorders
*SCIENTIFIC literature
*
*
*
*
Language
ISSN
0091-3022
Abstract
Hyperprolactinemia is an underappreciated/unknown adverse effects of antipsychotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attempt to reach a consensus among the experts; and 3, review by all of the authors of the final conclusions until reaching a complete consensus. We include recommendations on the appropriate time to act after hyperprolactinemia detection and discuss the evidence on available options: decreasing the dose of the antipsychotic drug, switching antipsychotics, adding aripiprazole, adding dopaminergic agonists, and other type of treatment. The consensus also included recommendations for some specific populations such as patients with a first psychotic episode and the pediatric-youth population, bipolar disorder, personality disorders and the elderly population. [ABSTRACT FROM AUTHOR]